1. Adams, G.E. and Stratford, I.J. Bioreductive drugs for cancer therapy: the search for tumor specificity. Int. J. Radiat. Oncol. Biol. Phys. 29: 231–238, 1994.
2. Archer, C.M., Edwards, B., Kelly, J.D., King, A.C., Burke, J.F. and Riley, A.L.M. Technetium labelled agents for imaging tissue hypoxia in vivo. In: Technetium and Rhenium in Chemistry and Nuclear Medicine, pp. 535–539. Editors: M. Nicolini, G. Bandoli and U. Mazzi. S.G. Editoriali, Padova, 1995.
3. Archer, C.M., Edwards, B. and Powell, N.A. Radiopharmaceuticals for imaging hypoxia. In: Current Directions in Radiopharmaceutical Research and Development, pp. 81–88. Editor: S.J. Mather. Kluwer Academic, Dordrecht, 1996.
4. Ballinger, J.R., Kee, J.W.M. and Rauth, A.M. In vitro and in vivo evaluation of a Technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J. Nucl. Med. 37: 1023–1031, 1996.
5. Brizel, D.M., Sibley, G.S., Prosnitz, L.R., Scher, R.L. and Dewhirst, M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38: 285–289, 1997.